Stories
Aurobindo Pharma Enters US Speciality Market with ADQUEY Launch
M
Moneycontrol•14-10-2026, 14:37
Aurobindo Pharma Enters US Speciality Market with ADQUEY Launch
- •Aurobindo Pharma has launched ADQUEY ointment in the US via its subsidiary Acrotech Biopharma, marking its entry into the dermatology market.
- •The move reflects a broader industry trend where Indian drugmakers are shifting from commoditised generics to higher-margin branded speciality therapies in the US.
- •ADQUEY is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis licensed from Japan's Otsuka Pharmaceutical.
- •The company has established a dedicated dermatology division to support ADQUEY and pave the way for future speciality product pipelines.
- •Speciality medications offer better profit margins and less competition, though they require significant investment in sales, marketing, and clinical development.
Key Questions Answered
Aurobindo Pharma launched ADQUEY (difamilast 1 percent) ointment in the US market through its subsidiary Acrotech Biopharma to treat mild-to-moderate atopic dermatitis.
ADQUEY was licensed from Japan's Otsuka Pharmaceutical, allowing Aurobindo to enter the market with a de-risked asset using Acrotech's commercial capabilities.
Intense competition, relentless price erosion, and buyer consolidation have made traditional generics less attractive, prompting companies to pursue higher-margin branded therapies with fewer competitors.
